10190-99-5 (马兜铃酸系统适用性 EP标准品,Phenanthro[3,4-d]-1,3-dioxole-5-carboxylicacid, 8-methoxy-6-nitro-, sodium salt (1:1))

马兜铃酸钠;6-氯-N-环丙基-3-哒嗪甲胺盐酸盐;马兜铃酸钠标准品;马兜铃酸钠盐;马兜铃酸系统适用性 EP标准品;8-甲氧基-6-硝基菲并[3,4-d]-1,3-二氧杂环戊烯-5-羧酸钠盐;

Phenanthro[3,4-d]-1,3-dioxole-5-carboxylicacid, 8-methoxy-6-nitro-, sodium salt (1:1);Aristolochic acid I sodium salt;ARISTOLOCHIC ACID SODIUM SALT;sodium,8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylate;Sodium aristolochate-I;Sodium 8-methoxy-6-nitrophenanthro(3,4-d)-1,3-dioxole-5-carboxylate;CAS-10190-99-5;NS00080607;sodium;8-methoxy-6-nitronaphtho[2,1-g][1,3]benzodioxole-5-carboxylate;UNII-KTM3D3H78E;Q27282434;Aristolocholic acid for system suitability, European Pharmacopoeia (EP) Reference Standard;PHENANTHRO(3,4-D)-1,3-DIOXOLE-5-CARBOXYLIC ACID, 8-METHOXY-6-NITRO-, SODIUM SALT (1:1);NCGC00257580-01;Aristolochic acid I sodium salt, powder, >=97%;CHEMBL3187459;EINECS 233-463-4;DTXCID7099;Sodium aristolochate;CCRIS 6498;Aristolochic acid, sodium salt (77% AA I, 21% AA II);DTXSID3020099;aristolochic acid I, sodium salt;MFCD00210760;FT-0645091;NIOSH/SF8281000;Tox21_200026;52232-70-9;10190-99-5;Sodium aristolate 1;SCHEMBL15537024;ARISTOLOCHIC ACID, SODIUM SALT [WHO-DD];Aristolochic acid, sodium salt;Phenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-, sodium salt;SF82810000;Aristolochic acid sodium salt (I and II) for biochemistry;Phenanthro[3,4-d]-1,3-dioxole-5-carboxylicacid,8-methoxy-6-nitro-,sodium salt(1:1);sodium 8-methoxy-6-nitrophenanthro[3,4-d][1,3]dioxole-5-carboxylate;8-Methoxy-6-nitrophenanthro(3,4-d)-1,3-dioxole-5-carboxylic acid sodium salt;KTM3D3H78E;Phenanthro[3,4-d]-1,3-dioxole-5-carboxylic acid, 8-methoxy-6-nitro-, sodium salt (1:1);G78080;

MFCD00210760

BQVOPWJSBBMGBR-UHFFFAOYSA-M

1S/C17H11NO7.Na/c1-23-12-4-2-3-8-9(12)5-11(18(21)22)14-10(17(19)20)6-13-16(15(8)14)25-7-24-13;/h2-6H,7H2,1H3,(H,19,20);/q;+1/p-1

[Na+].O1COC2=CC(C(=O)[O-])=C3C(=CC4C(=CC=CC=4C3=C12)OC)[N+](=O)[O-]

233-463-4